Literature DB >> 23529615

Differing effects of interleukin-10 on cutaneous and pulmonary Francisella tularensis live vaccine strain infection.

Dennis W Metzger1, Sharon L Salmon, Girish Kirimanjeswara.   

Abstract

We investigated the role of interleukin-10 (IL-10) in cutaneous and pulmonary infection with Francisella tularensis. We found that after intradermal challenge of mice with the live vaccine strain (LVS) of F. tularensis, splenic IL-10 levels increased rapidly and reached a peak 5 days after infection. However, IL-10 expression after infection was detrimental, since IL-10(-/-) mice showed increased bacterial clearance and were resistant to an infectious dose (>10(6) CFU/mouse) that was uniformly lethal for IL-10(+/+) mice. Furthermore, IL-10(+/+) mice treated with neutralizing anti-IL-10R monoclonal antibody were able to survive lethal cutaneous LVS challenge. The presence of IL-10 appeared to restrain the expression of IL-17, since high levels of splenic IL-17 were observed after intradermal LVS infection only in IL-10(-/-) mice. Furthermore, treatment with neutralizing anti-IL-17R antibody ablated the enhanced survival observed in IL-10(-/-) mice. However, neutralization of IL-10 activity in IL-17R(-/-) mice failed to provide protection. Thus, IL-10 suppresses a protective IL-17 response that is necessary for resistance to cutaneous LVS infection. Surprisingly, however, IL-10(-/-) mice were significantly more susceptible to pulmonary infection with LVS. Finally, although IL-10 is a critical and novel regulator of immunity to F. tularensis LVS infection, its effects were masked during infection with the highly virulent SchuS4 strain. Taken together, these findings suggest that differentially regulating expression of the IL-10 pathway in various tissues could ultimately have prophylactic and therapeutic benefits for protection against tularemia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23529615      PMCID: PMC3676042          DOI: 10.1128/IAI.00024-13

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  Francisella tularensis-infected macrophages release prostaglandin E2 that blocks T cell proliferation and promotes a Th2-like response.

Authors:  Matthew D Woolard; Justin E Wilson; Lucinda L Hensley; Leigh A Jania; Thomas H Kawula; James R Drake; Jeffrey A Frelinger
Journal:  J Immunol       Date:  2007-02-15       Impact factor: 5.422

2.  Francisella tularensis: a red-blooded pathogen.

Authors:  J Wayne Conlan
Journal:  J Infect Dis       Date:  2011-07-01       Impact factor: 5.226

3.  Development of tolerogenic dendritic cells and regulatory T cells favors exponential bacterial growth and survival during early respiratory tularemia.

Authors:  Sivakumar Periasamy; Anju Singh; Bikash Sahay; Tabassum Rahman; Paul J Feustel; Giang H Pham; Edmund J Gosselin; Timothy J Sellati
Journal:  J Leukoc Biol       Date:  2011-07-01       Impact factor: 4.962

4.  Lung CD4-CD8- double-negative T cells are prominent producers of IL-17A and IFN-gamma during primary respiratory murine infection with Francisella tularensis live vaccine strain.

Authors:  Siobhán C Cowley; Anda I Meierovics; Jeffrey A Frelinger; Yoichiro Iwakura; Karen L Elkins
Journal:  J Immunol       Date:  2010-04-14       Impact factor: 5.422

5.  A detrimental effect of interleukin-10 on protective pulmonary humoral immunity during primary influenza A virus infection.

Authors:  Keer Sun; Luisa Torres; Dennis W Metzger
Journal:  J Virol       Date:  2010-03-03       Impact factor: 5.103

Review 6.  Subversion of host recognition and defense systems by Francisella spp.

Authors:  Crystal L Jones; Brooke A Napier; Timothy R Sampson; Anna C Llewellyn; Max R Schroeder; David S Weiss
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

7.  Novel modification of lipid A of Francisella tularensis.

Authors:  Nancy J Phillips; Birgit Schilling; Molly K McLendon; Michael A Apicella; Bradford W Gibson
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

8.  Interleukin-10 promotes Mycobacterium tuberculosis disease progression in CBA/J mice.

Authors:  Gillian L Beamer; David K Flaherty; Barnabe D Assogba; Paul Stromberg; Mercedes Gonzalez-Juarrero; Rene de Waal Malefyt; Bridget Vesosky; Joanne Turner
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

9.  Administration of interleukin-10 abolishes innate resistance to Listeria monocytogenes.

Authors:  J P Kelly; G J Bancroft
Journal:  Eur J Immunol       Date:  1996-02       Impact factor: 5.532

10.  Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10.

Authors:  Jie Sun; Rajat Madan; Christopher L Karp; Thomas J Braciale
Journal:  Nat Med       Date:  2009-02-22       Impact factor: 53.440

View more
  13 in total

1.  Identification of early interactions between Francisella and the host.

Authors:  Lydia M Roberts; Shraddha Tuladhar; Shaun P Steele; Kristina J Riebe; Ching-Ju Chen; R Ian Cumming; Sarah Seay; Richard Frothingham; Gregory D Sempowski; Thomas H Kawula; Jeffrey A Frelinger
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

2.  Interleukin-10 plays a key role in the modulation of neutrophils recruitment and lung inflammation during infection by Streptococcus pneumoniae.

Authors:  Hernán F Peñaloza; Pamela A Nieto; Natalia Muñoz-Durango; Francisco J Salazar-Echegarai; Javiera Torres; María J Parga; Manuel Alvarez-Lobos; Claudia A Riedel; Alexis M Kalergis; Susan M Bueno
Journal:  Immunology       Date:  2015-09       Impact factor: 7.397

3.  IL-10 suppresses IL-17-mediated dermal inflammation and reduces the systemic burden of Vaccinia virus in a mouse model of eczema vaccinatum.

Authors:  Alanna R Darling; Eva-Jasmin Freyschmidt; Oliver T Burton; Kyle J Koleoglou; Michiko K Oyoshi; Hans C Oettgen
Journal:  Clin Immunol       Date:  2013-11-27       Impact factor: 3.969

4.  IL-10 restrains IL-17 to limit lung pathology characteristics following pulmonary infection with Francisella tularensis live vaccine strain.

Authors:  Samantha R Slight; Leticia Monin; Radha Gopal; Lyndsay Avery; Marci Davis; Hillary Cleveland; Tim D Oury; Javier Rangel-Moreno; Shabaana A Khader
Journal:  Am J Pathol       Date:  2013-09-03       Impact factor: 4.307

Review 5.  The immunobiology of toll-like receptor 4 agonists: from endotoxin tolerance to immunoadjuvants.

Authors:  Julia K Bohannon; Antonio Hernandez; Perenlei Enkhbaatar; William L Adams; Edward R Sherwood
Journal:  Shock       Date:  2013-12       Impact factor: 3.454

6.  Individualized significance of the -251 A/T single nucleotide polymorphism of interleukin-8 in severe infections.

Authors:  M D Georgitsi; V Vitoros; C Panou; I Tsangaris; E Aimoniotou; N K Gatselis; E Chasou; G Kouliatsis; K Leventogiannis; D Velissaris; E Belesiotou; O Dioritou-Aggaliadou; E Giannitsioti; M G Netea; E J Giamarellos-Bourboulis; G Giannikopoulos; Z Alexiou; N Voloudakis; A Koutsoukou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-01-14       Impact factor: 3.267

Review 7.  Uncovering the components of the Francisella tularensis virulence stealth strategy.

Authors:  Bradley D Jones; Matthew Faron; Jed A Rasmussen; Joshua R Fletcher
Journal:  Front Cell Infect Microbiol       Date:  2014-03-07       Impact factor: 5.293

Review 8.  Host-pathogen interactions and immune evasion strategies in Francisella tularensis pathogenicity.

Authors:  Don J Steiner; Yoichi Furuya; Dennis W Metzger
Journal:  Infect Drug Resist       Date:  2014-09-18       Impact factor: 4.003

9.  Protective or deleterious role of scavenger receptors SR-A and CD36 on host resistance to Staphylococcus aureus depends on the site of infection.

Authors:  Charlène Blanchet; Gregory Jouvion; Catherine Fitting; Jean-Marc Cavaillon; Minou Adib-Conquy
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

Review 10.  Is boosting the immune system in sepsis appropriate?

Authors:  Jean-Marc Cavaillon; Damon Eisen; Djilalli Annane
Journal:  Crit Care       Date:  2014-03-24       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.